This Phase II trial is evaluating the safety and effectiveness of 3 oral drugs (Asciminib, Imatinib, Nilotinib) in patients that have been pre-treated for Chronic Myeloid Leukaemia (CML).
This trial is treating patients with Chronic Myeloid Leukaemia (CML).
This is a systemic therapy trial.
You may be able to join this trial if:
- You are currently receiving treatment for your cancer.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
In this trial, patients will be randomised to receive either combination therapy with Asciminib (60 mg) and Imatinib (400 mg) once daily, or receive Imatinib (400mg once daily) or Nilotinib (300mg twice daily) alone.
Recruiting Hospitals Read More